Assert-IQ vs Lung AI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

Lung AI

by Multiple (e.g., RevealDx, Optellum, LungLife AI, Qure.ai, Arterys, DeepHealth, HeartLung.AI)

AI Verdict

Assert-IQ is an insertable cardiac monitor system designed for long-term, continuous detection and management of heart rhythm disorders. In contrast, Lung AI offers a handheld ultrasound platform with AI for real-time imaging and assessment of both cardiac and lung conditions, focusing on immediate diagnostic insights at the point of care. While both leverage AI in cardiology, their core technologies and primary use cases—long-term rhythm monitoring versus real-time imaging—are distinct.

Choose Assert-IQ if…

Choose Assert-IQ if your primary need is long-term, continuous, and passive monitoring for suspected heart rhythm disorders. This system is ideal for diagnosing infrequent or asymptomatic arrhythmias over an extended period, providing comprehensive data for chronic management.

View Assert-IQ →

Choose Lung AI if…

Choose Lung AI if you require immediate, real-time diagnostic imaging at the point of care for rapid assessment of lung or cardiac conditions. This handheld AI ultrasound is best suited for acute settings, emergency medicine, or situations where quick, on-device AI-powered insights are crucial for critical decision-making.

View Lung AI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	Lung AI
Deployment	Subcutaneously implanted device with mobile app connectivity	Cloud-based, integrated with existing platforms (e.g., RapidAI), and potentially on-premise.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool B (Lung AI) emphasizes 'easy-to-use medical imaging' and features 'Guided image capture for optimal scans' and 'Exo U (AI-powered POCUS education and training)', making advanced ultrasound more accessible. Tool A (Assert-IQ) focuses on a minimally invasive insertion and remote monitoring, which is convenient for long-term use, but Tool B's active guidance for real-time diagnostics offers a more direct and empowering user experience for clinicians performing scans.

Clinical Value

Lung AI

Tool B (Lung AI) provides real-time AI-powered detection for critical conditions like pleural effusion, consolidation/atelectasis, and cardiac indicators directly at the point of care, enabling immediate diagnostic and therapeutic decisions. While Tool A (Assert-IQ) offers invaluable long-term continuous cardiac monitoring for elusive arrhythmias, Tool B's immediate, on-device insights across multiple critical areas offer a broader and more acute clinical impact for rapid patient assessment.

Pricing & Value

Tie

Both Tool A (Assert-IQ) and Tool B (Lung AI) have opaque pricing structures, requiring direct contact for institutional or enterprise pricing. Neither tool provides specific cost details or offers a free trial, making a direct comparison of their financial value impossible based on the available information.

Enterprise Readiness

Assert-IQ

Tool A (Assert-IQ) is offered by Abbott Medical, a long-established global medical device company, explicitly targeting 'Large health systems, hospitals, cardiology clinics' and offering a hybrid deployment. While Tool B (Lung AI) is HIPAA compliant and FDA cleared with a BAA, Abbott's extensive history, established infrastructure, and explicit enterprise focus suggest a more mature and robust readiness for large-scale institutional adoption and support.

Innovation

Lung AI

Tool B (Lung AI) demonstrates higher innovation by pioneering a handheld ultrasound platform with integrated, on-device AI for real-time detection, guided image capture, and educational support (Exo U). This approach significantly democratizes advanced imaging and AI diagnostics at the point of care, operating without internet dependency. Tool A (Assert-IQ) offers advanced long-term cardiac monitoring, which is a refinement of existing ICM technology, rather than a fundamentally new approach to diagnostic imaging.

Support & Docs

Lung AI

Tool B (Lung AI) explicitly highlights 'Exo U (AI-powered POCUS education and training)' as a key feature, directly addressing user education and proficiency, which is a critical aspect of support for a new technology. While Tool A (Assert-IQ), being from Abbott, is expected to have comprehensive support, the provided facts do not explicitly detail its support or documentation offerings, giving Tool B an advantage in this dimension based on available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	Lung AI
Primary Function	Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders.	High-performance, handheld ultrasound platform that uses artificial intelligence for imaging and therapeutic applications, enabling real-time decisions.
Company	Abbott Medical	Exo
Key Feature (Cardiac Monitoring/Detection)	Long-term continuous cardiac monitoring (up to 6 years)	Automated AI-based indicators for cardiac conditions (e.g., heart failure, hypertrophy)
Key Feature (Other AI/Diagnostic Capability)	Advanced arrhythmia detection algorithms	AI-powered detection of pleural effusion
Target Specialties	Cardiology, Internal Medicine	Cardiology, Emergency Medicine, Pulmonology
Mobile App Availability	none	Not specified